Purpose: Plasma cell-free DNA (cfDNA) genotyping is increasingly used in cancer care, but
assay accuracy has been debated. Because most cfDNA is derived from peripheral blood …

Background Blood-based biomarkers of anti-solid tumor immune checkpoint blockade (ICB)
response are lacking. We hypothesized that changes in systemic cytokine levels with the …

Objectives Plasma genotyping represents an opportunity for convenient detection of
clinically actionable mutations in advanced cancer patients, such has been well …

Objectives Quantifying tumor DNA in tissue and circulating in blood permits high-quality
molecular monitoring to detect and track cancer progression. Evaluating tumor DNA in both …

Background Tumor genotyping is transforming lung cancer care but requires adequate
tumor tissue. Advances in minimally invasive biopsy techniques have increased access to …

Background Targeted sequencing using oncopanels requires comprehensive assessments
of accuracy and detection sensitivity to ensure analytical validity. By employing reference …

PURPOSE Plasma circulating tumor DNA (ctDNA) analysis is routine for genotyping of
advanced non–small-cell lung cancer (NSCLC); however, early response assessment using …

Objective Pancreatic ductal adenocarcinoma (PDAC) is commonly diagnosed at an
advanced stage. Liquid biopsy approaches may facilitate detection of early stage PDAC …

BACKGROUND Although interest in droplet-digital PCR technology (ddPCR) for cell-free
circulating DNA (cfDNA) analysis is burgeoning, the technology is compromised by …

Protein N-terminal acetylation is predominantly a ribosome-associated modification, with
NatA-E serving as the major enzymes. NatC is the most unusual of these enzymes …